Review Article

Activators and Inhibitors of NRF2: A Review of Their Potential for Clinical Development

Natalia Robledinos-Antón,^{1,2} Raquel Fernández-Ginés,^{1,2} Gina Manda^{ID},³
and Antonio Cuadrado^{ID}^{1,2,3}

¹*Instituto de Investigaciones Biomédicas “Alberto Sols” UAM-CSIC, Instituto de Investigación Sanitaria La Paz (IdiPaz) and Department of Biochemistry, Faculty of Medicine, Autonomous University of Madrid, Madrid, Spain*

²*Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), ISCIII, Madrid, Spain*

³*Victor Babes National Institute of Pathology, Bucharest, Romania*

Correspondence should be addressed to Antonio Cuadrado; antonio.cuadrado@uam.es

Received 16 January 2019; Revised 26 March 2019; Accepted 16 April 2019; Published 14 July 2019

Academic Editor: Luciano Saso

Copyright © 2019 Natalia Robledinos-Antón et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The transcription factor NRF2 (nuclear factor erythroid 2-related factor 2) triggers the first line of homeostatic responses against a plethora of environmental or endogenous deviations in redox metabolism, proteostasis, inflammation, etc. Therefore, pharmacological activation of NRF2 is a promising therapeutic approach for several chronic diseases that are underlined by oxidative stress and inflammation, such as neurodegenerative, cardiovascular, and metabolic diseases. A particular case is cancer, where NRF2 confers a survival advantage to constituted tumors, and therefore, NRF2 inhibition is desired. This review describes the electrophilic and nonelectrophilic NRF2 activators with clinical projection in various chronic diseases. We also analyze the status of NRF2 inhibitors, which at this time provide proof of concept for blocking NRF2 activity in cancer therapy.

1. Introduction

Nuclear factor erythroid 2-related factor 2 (NRF2) is the product of the *NFE2L2* gene and belongs to the cap'n'collar transcription factor family. By sequence homology with other orthologs, the domains termed Neh1-7 have been traditionally allocated in this protein (Figure 1(a)). At the C-terminus, NRF2 contains a basic leucine-zipper (bZip) domain that participates in the formation of heterodimers with other bZip proteins, like small muscle aponeurosis fibromatosis (MAF) K, G, and F [1, 2]. These heterodimers regulate the expression of about 250 human genes that present a regulatory enhancer sequence termed Antioxidant Response Element (ARE; 5'-TGACNNNGC-3') and participate in multiple homeostatic functions including regulation of inflammation, redox metabolism, and proteostasis [3–6].

From a clinical perspective, it is of utmost importance that NRF2 can be targeted pharmacologically in diseases underlined by oxidative stress and inflammation, such as neurodegenerative, vascular, and metabolic diseases as well as cancer [7, 8]. In models of most chronic diseases, a reinforcement of homeostasis through NRF2 activators provides a beneficial therapeutic effect. In cancer, the pharmacological regulation of NRF2 appears to be context dependent. It is generally accepted that NRF2 inhibitors not only reduce the survival and proliferative advantage of cancer cells but also sensitize tumors to chemo- and radiotherapy [9]. In this review, we describe the pharmacological activators of NRF2 that are in several stages of pharmacological development for the treatment of several chronic diseases. The most developed compounds activate NRF2 by preventing its degradation by KEAP1-dependent mechanisms. We also discuss

FIGURE 1: Domain structures of NRF2 and KEAP1. (a) Domain structure of NRF2. NRF2 possesses six highly conserved domains called NRF2-ECH homology (Neh) domains [167]. The functional role of each Neh domain is specified. Within the Neh2 domain, the low-affinity (DLG) and high-affinity (ETGE) binding domains to KEAP1 are zoomed in. (b) Domain structure of a KEAP1 monomer showing the position of cysteine residues. The N-terminal BTB (bric-a-brac, tramtrack, broad complex) domain participates in homodimerization and binding to CUL3/RBX1. The C-terminal region, DGR (double glycine repeat) domain, contains a double glycine repeat called Kelch repeat that binds NRF2-Neh2 domain. The intervening region (IVR/LR) connects BTB and DGR domains and is particularly rich in redox-sensitive cysteine residues. Red and blue cysteine residues in KEAP1 are the most relevant for electrophile reactivity. This figure has been modified and extended from [168] to highlight the degradation domains in NRF2 and the cysteines of KEAP1.

the current state of NRF2 inhibitors which may be highly relevant for cancer therapeutics although at this time they are still in early phases of development.

2. Physiologic Regulation of NRF2

NRF2 is ubiquitously and constitutively expressed by cells, thus ensuring their prompt protective response to oxidative, inflammatory, and metabolic stresses. Under normal physiological conditions, NRF2 has a rapid turnover and presents a half-life of about 20-30 min due to its constant degradation by the ubiquitin proteasome system [10, 11]. Therefore, under nonstressed conditions, low NRF2 levels provide basal expression of its target genes.

The main control of NRF2 stability is exerted by the E3 ligase adapter Kelch-like ECH-associated protein 1 (KEAP1). KEAP1 is a homodimer protein that comprises three functional domains (Figure 1(b)): a broad complex, tramtrack, bric-a-brac (BTB) homodimerization domain, an intervening region (IVR), and a C-terminal Kelch domain with a double glycine repeat (DGR). The Kelch domain binds to the

Neh2 domain of NRF2 at two amino acid sequences: DLG and ETGE. Experiments based on isothermal calorimetry have led to the conclusion that the ETGE motif exhibits about one hundred times higher affinity for KEAP1 than the DLG motif [12]. KEAP1 presents NRF2 for ubiquitination by the E3 ligase complex formed by Cullin3 and RBX1 proteins (CUL3/RBX1) [13], resulting in subsequent NRF2 degradation by the proteasome 26S [2, 14].

KEAP1 contains 27 cysteine residues in humans, converting this protein in a redox sensor for endogenous and environmental oxidative signals as well as for electrophilic reactions [15]. Under redox-challenging conditions, the cellular redox buffers comprising glutathione (GSH), thioredoxin, etc. maintain low intracellular levels of reactive oxygen species (ROS) and glutathionylated proteins. However, ROS oxidize thiols and induce glutathionylation and alkylation of macromolecules, therefore having the capacity to modify KEAP1 cysteines [16]. From a pharmacological perspective, electrophile reaction with some cysteines of KEAP1 leads to the formation of adducts that prevent the ubiquitination NRF2, resulting in its stabilization, nuclear

translocation, and transcriptional induction of NRF2-target genes [7, 8].

An alternative mechanism for proteasomal degradation of NRF2 is mediated by the glycogen synthase kinase 3 (GSK-3) and the E3 ligase adapter β -TrCP. GSK-3 α and β are serine/threonine protein kinases involved in several signaling pathways such as receptor tyrosine kinase, WNT, and Hedgehog that influence cell division, survival, and development [17, 18]. GSK-3 α and β are maintained in an inactive state under normal conditions due to their inhibition by AKT-mediated phosphorylation at their N-terminal pseudosubstrate domain or by sequestration in protein complexes. However, in the absence of receptor signaling, active GSK-3 phosphorylates NRF2 at the Neh6 domain (DSGIS). This phosphodomain recruits β -TrCP, which recognizes pSGIPs, and the CUL1/RBX1 complex for ubiquitin-proteasome degradation [19]. β -TrCP also recognizes another motif in the Neh6 domain of NRF2 (DSAPGS) which appears to be constitutively phosphorylated in a GSK-3-independent manner [20]. Additional degradative systems are able to regulate NRF2 at posttranscriptional level, such as the inositol-requiring enzyme (IRE1)/E3 ubiquitin ligase synoviolin (HRD1) [21].

NRF2 can be regulated at the transcriptional level. The *NFE2L2* gene promoter presents several regulatory sequences: (a) one xenobiotic response element (XRE; 5'-TA/TGCG TGA/C-3') at -712 and two XRE-like sequences at +755 and +850 that are recognized by the transcription factor Aryl Hydrocarbon Receptor (AHR) [22]; (b) two ARE-like sequences at -492 (AREL1; TGACTCCGC) and -754 pb (AREL2; TGAAGTGGC), which allow NRF2 autoregulation [23]; (c) one 12-O-tetradecanoylphorbol-13-acetate-response element (TRE) (TGCGTCA) at +267 to +273 pb that is activated by the oncogenic KRAS [24], BRAF, and MYC [25] hence being critically involved in carcinogenesis; (d) one NF- κ B binding site that responds to inflammatory stimuli [26]; and (e) epigenetic changes such as promoter methylation, microRNAs including miR-144 [27], miR-28 [28], miR-98-5p [29], and long noncoding RNA deregulation [30] that contribute to changes in expression of the NRF2-coding gene.

3. Pharmacologic Activators of NRF2

The so-called “NRF2 activators” should be more precisely termed “KEAP1 inhibitors” as their molecular target is in fact KEAP1 [31]. These compounds can be classified as electrophiles, protein-protein interaction (PPI) inhibitors, and multitarget drugs (Figure 2).

3.1. Electrophilic Compounds. Most pharmacological NRF2 activators are electrophilic molecules that covalently modify cysteine residues present in the thiol-rich KEAP1 protein by oxidation or alkylation [32–34]. Many cysteines of KEAP1 are modified by different electrophiles [35–37]. Cysteines Cys-151, Cys-273, and Cys-288 [38, 39] appear to be the most susceptible to electrophile reaction [40, 41]. Other sensitive cysteines are Cys-226, Cys-434, and Cys-613. This “cysteine-code” controls KEAP1 activity when the protective

response mediated by NRF2 is needed. Selected electrophilic activators of NRF2 that are in various stages of clinical development are presented in Table 1.

One mechanism of KEAP1 inhibition is the sequestration in complexes with NRF2 that cannot be ubiquitinated. Modifications of several cysteines in KEAP1 generate a non-functional closed state with both Neh2 motifs (DLG and ETGE) of NRF2 interacting with the KEAP1 dimer but not leading to ubiquitination. As a result, free KEAP1 is not regenerated at a sufficient rate and newly synthesized NRF2 escapes KEAP1-mediated ubiquitination and subsequent degradation [42].

Another mechanism of KEAP1 inhibition is related to its interaction with the CUL3/RBX1 complex, required for NRF2 ubiquitination. Cys-151 located at the BTB domain influences the interaction of KEAP1 with CUL3. The crystal structure of the BTB domain bound to the pentacyclic triterpenoid 2-cyano-3,12-dioxo-oleana-1,9(11)-dien-28-oate (bardoxolone, CDDO, RTA401) indicates that adduct formation with Cys-151 most likely disrupts the interaction between KEAP1 and CUL3 [43–45]. As a result, KEAP1 is clogged in a NRF2 bound conformation, and newly formed NRF2 escapes ubiquitination. Synthetic triterpenoids have been derived from the natural compound oleanolic acid to provide them with strong Michael acceptor reactivity. This is achieved mainly through the addition of enone and cyano groups to the A ring and another enone group to the C ring [46, 47]. Bardoxolone methyl (CDDO-Me or RTA 402) reached clinical trials for the treatment of advanced chronic kidney disease (CKD) and type 2 diabetes mellitus [48]. Although phase II clinical trials demonstrated long-term increment in glomerular filtration, CDDO-Me was halted at phase III due to cardiovascular safety issues [49]. A new phase II clinical trial has recently started recruiting patients with rare chronic kidney diseases to better define the safety and efficacy profiles of CDDO-Me. Currently, CDDO-Me is also under clinical study for the Alport syndrome and pulmonary hypertension. In an effort to improve the safety profile, a second-generation difluoromethyl acetamide derivative of bardoxolone methyl, called RTA-408 (Omaveloxone), is now under clinical investigation in phase II clinical trials for Friedreich's ataxia, ocular inflammation, and pain after ocular surgery [50]. Recently, a preclinical study evaluated RTA-408 for diabetic wound recovery and pointed NRF2 upregulation as responsible for the observed improvement in regenerative capacity [51].

The most successful NRF2 activator to date is the fumaric acid ester dimethyl fumarate (DMF) (BG-12 or Tecfidera, from Biogen) that has been approved in 2013 by FDA for relapsing-remitting multiple sclerosis (MS) [52–55]. Previously, DMF was authorized for the treatment of psoriasis [56]. DMF was shown to reduce the number of peripheral T cells, CD8⁺ cells being more sensitive to DMF than CD4⁺ cells [57, 58]. DMF also reduces total B lymphocyte counts, especially memory B cells, along with a decrease in granulocyte-macrophage colony-stimulating factor, IL-6, and TNF- α production, leading to an anti-inflammatory shift in B cell responses [59, 60]. The DMF-induced activation of NRF2 in the central nervous system was described

FIGURE 2: Summary of the pharmacological strategies to modulate NRF2 activity.

in the MS mice model of experimental allergic encephalomyelitis [61]. In this model, DMF-dependent NRF2 activation correlated with an improvement in the clinical course of MS, favored axon preservation, and increased astrocyte activation. These beneficial effects of DMF did not occur in NRF2-null mice, hence indicating that DMF was acting mainly by targeting the NRF2 pathway. DMF is mostly converted to monomethyl fumarate (MMF) by intestinal esterases, and only a small fraction is found in blood conjugated with glutathione [62]. Therefore, an oral formulation of a monomethyl fumarate (MMF) derivative, diroximel fumarate (2-(2,5-dioxo-1-pyrrolidinyl)ethyl ester; ALKS-8700; Alkermes) which exhibits improved bioavailability and efficacy, is currently under phase III trial for MS [63, 64]. However, the biological effects of these fumaric acid esters are not fully characterized and KEAP1/NRF2-independent effects are being described. For instance, it has been reported that

DMF and MMF activate the nicotinic receptor hydroxycarboxylic acid receptor 2, which is expressed in immune cells and gut epithelial cells, resulting in NRF2-independent anti-inflammatory responses [65].

Oltipraz (4-methyl-5-(pyrazinyl-2)-1,2-dithiole-3-thione) is a NRF2 inducer that enhances GSH biosynthesis and phase II detoxification enzymes, such as NQO1. Oltipraz is a promising chemopreventive agent [66] under phase III clinical trial for the treatment of nonalcoholic fatty liver disease.

Ursodiol (ursodeoxycholic acid) is an FDA-approved drug for the treatment of primary biliary cirrhosis. Although its cytoprotective mechanisms have not been elucidated yet, several research groups suggested that the upregulation of NRF2 by ursodiol induces detoxification and antioxidant mechanisms that play a role in its therapeutic efficacy [67, 68].

Several natural compounds have been identified as electrophilic NRF2 inducers, including sulforaphane, curcumin,

TABLE 1: Selected electrophilic activators of NRF2 under clinical development.

Compound	Type	Mechanism of action	Disease	Clinical trial	ClinicalTrials.gov identifier
<div>Bardoxolone-methyl (CDDO-Me) </div>	Synthetic triterpenoids	Electrophilic modification of KEAP1-Cys-151	Diabetic nephropathy	Phase II	NCT00811889
			IgA nephropathy		
			CKD associated with type 1 diabetes	Phase II	NCT03366337
			Focal segmental glomerulosclerosis		
			Autosomal dominant polycystic kidney		
			Chronic kidney disease	Phase III	NCT01351675
			Type 2 diabetes		
			Diabetic nephropathy	Phase I/II	NCT00550849
			Liver disease		
			Hepatic impairment	Phase I	NCT01563562
<div>RTA-408 (omaveloxolone) </div>	Synthetic triterpenoids	Electrophilic modification of KEAP1-Cys-151	Healthy	Phase I	NCT00529438
			Advanced solid tumors lymphoid malignancies	Phase I	NCT00508807
			Alport syndrome	Phase II/III cardinal	NCT03019185
			Pulmonary hypertension	Phase III RANGER	NCT03068130
			Pulmonary arterial hypertension	Phase III	NCT02657356
			Renal insufficiency, chronic		
			Diabetes mellitus, type 2	Phase II	NCT01053936
			Mitochondrial myopathy	Phase II	NCT02255422
			Friedreich's ataxia	Phase II	NCT02255435
			Inflammation and pain following ocular surgery	Phase II	NCT02065375
<div>Dimethyl fumarate </div>	Fumaric acid ester	Electrophilic modification of KEAP1-Cys-151	Corneal endothelial cell loss	Phase II	NCT02128113
			Ocular pain		
			Ocular inflammation		
			Cataract surgery		
			Melanoma	Phase I/II	NCT02259231
			Breast cancer	Phase II	NCT02142959
			Multiple sclerosis	Approved	
			Psoriasis	Approved	
			Rheumatoid arthritis	Phase II	NCT00810836
			Adult brain glioblastoma	Phase I	NCT02337426
<div>Dimethyl fumarate </div>	Fumaric acid ester	Electrophilic modification of KEAP1-Cys-151	Cutaneous T cell lymphoma	Phase II	NCT02546440
			Obstructive sleep apnea	Phase II	NCT02438137
			Chronic lymphocytic leukemia	Phase I	NCT02784834
<div>Dimethyl fumarate </div>	Fumaric acid ester	Electrophilic modification of KEAP1-Cys-151	Small lymphocytic lymphoma		

TABLE 1: Continued.

Compound	Type	Mechanism of action	Disease	Clinical trial	ClinicalTrials.gov identifier
<div>ALKS-8700</div> <div> </div>	Fumaric acid ester (MMF-derivate)	Electrophilic modification of KEAP1-Cys-151	Multiple sclerosis	Phase III	NCT02634307
<div>Oltipraz</div> <div> </div>	Organosulfur compound	Electrophilic modification of KEAP1-Cys-151	Nonalcoholic steatohepatitis Schistosomiasis	Phase III <i>Approved</i>	NCT02068339
<div>Ursodiol</div> <div> </div>	Biliary acid	Electrophilic modification of KEAP1-Cys-151	Cholestasis Diarrhea Cholelithiasis Primary biliary cirrhosis Barrett esophagus Low-grade dysplasia Chronic hepatitis C Type 2 diabetes mellitus	Phase II/III Phase IV Phase III Phase IV Phase II Phase III Phase II	NCT00846963 NCT02748616 NCT02721862 NCT01510860 NCT01097304 NCT00200343 NCT02033876
<div>Sulforaphane</div> <div> </div>	Isothiocyanate	Electrophilic modification of KEAP1-Cys-151	Schizophrenia COPD Atopic asthmatics Autism spectrum disorder Healthy Melanoma Asthma Prostate cancer	Phase II/III Phase II Phase II Phase II Phase I Phase II Phase II Phase II Phase II Phase I/II Phase I Phase I Phase I Phase I Phase I/II Phase II	NCT02880462 NCT02810964 NCT01716858 NCT01335971 NCT01845493 NCT01474993 NCT02909959 NCT02677051 NCT02654743 NCT02561481 NCT01008826 NCT02023931 NCT01568996 NCT01845493 NCT01183923 NCT01228084

TABLE 1: Continued.

Compound	Type	Mechanism of action	Disease	Clinical trial	ClinicalTrials.gov identifier
Sulforadex (SFX-01)	Sulforaphane/alpha-cyclodextrin complex	Electrophilic modification of KEAP1-Cys-151	Breast cancer	Phase II	NCT00843167
			Lung cancer	Phase II	NCT03232138
			Environmental carcinogenesis	Phase II	NCT01437501
			Alcohol sensitivity	Phase II	NCT01845220
			Aging	Phase II	NCT03126539
			Rhinitis, allergic	Phase II	NCT02885025
			Helicobacter pylori infection	Phase IV	NCT03220542
			Diabetes mellitus, noninsulin-dependent	Phase II	NCT02801448
			Subarachnoid haemorrhage	Phase II	NCT02614742
			Breast neoplasm	Phase I/II	NCT02970682
ITH12674	Melatonin-sulforaphane hybrid	Electrophilic modification of KEAP1-Cys-151	Brain ischemia	Preclinical PK	No clinical trials available
			Prostate cancer	Phase I	NCT02055716 NCT01948362
Curcumin	Stilbene	Electrophilic modification of KEAP1-Cys-151	Type 2 diabetes	Phase IV	NCT01052025
			Prediabetes	Phase I/II	NCT02104752
			Insulin resistance	Phase II/III	NCT01225094
			Cardiovascular risk		
			Schizophrenia		
			Cognition		
			Psychosis		
			Acute kidney injury		
			Abdominal aortic aneurysm		

TABLE 1: Continued.

Compound	Type	Mechanism of action	Disease	Clinical trial	ClinicalTrials.gov identifier
Resveratrol	(E)-Stilbene derivative	Electrophilic modification of KEAP1-Cys-151	Chronic kidney diseases	Phase II/III	NCT03262363
			Diabetes mellitus, type 2 Polymorphism	Phase I/II	NCT00164749
			Alzheimer's disease	Phase II	NCT02944578
			Neoplasms	Phase III	NCT02255370
			Crohn's disease	Phase IV	NCT02298985
			Chronic schizophrenia	Phase II	NCT01811381
			Mild cognitive impairment	Phase III	NCT02064673
			Prostate cancer	Phase IV	NCT01750359
			Major depression	Phase I	NCT01677611
			Type 2 diabetes	Phase I	NCT00256334
CXA-10	Nitro-fatty acid (NFA)	Electrophilic modification of KEAP1-Cys-273 and Cys-288	Colon cancer	N/A	NCT02245932
			COPD	Phase I/II	NCT01339884
			Friedreich ataxia	Phase II/III	NCT02030977
			Nonalcoholic fatty liver	Phase III	NCT01914081
			Nonischemic cardiomyopathy	Phase IV	NCT02475564
			Endometriosis	Phase III	NCT02433925
			Chronic renal insufficiency	Phase II	NCT02114892
			Metabolic syndrome X	Phase III	NCT01492114
			Chronic subclinical inflammation	Phase II	NCT01504854
			Redox status	Phase III	NCT00743743
CXA-10	Nitro-fatty acid (NFA)	Electrophilic modification of KEAP1-Cys-273 and Cys-288	Alzheimer's disease	Phase III	NCT02336633
			Huntington disease	Phase I	NCT02248051
			Acute kidney injury	Phase II	NCT03449524
CXA-10	Nitro-fatty acid (NFA)	Electrophilic modification of KEAP1-Cys-273 and Cys-288	Pulmonary arterial hypertension (PAH)	Phase II	NCT03449524
			Primary focal segmental glomerulosclerosis (FSGS)	Phase II	NCT03422510

resveratrol, quercetin, genistein, and more recently andrographolide [69]. For instance, sulforaphane (SFN), an isothiocyanate found in cruciferous vegetables, has been successfully used for the treatment of patients with type II diabetes mellitus [70, 71]. Due to the capacity of SFN to cross the blood-brain barrier, it protects against neurodegenerative disorders as demonstrated in murine models of disease. Regarding acute brain damage, SFN was shown to exert protective effects in hypoxic-ischemic injury in rats by reducing the infarct ratio and by upregulating NRF2 and HO-1 [72, 73]. In neurodegenerative disease models, SFN proved protective capacity against the neurotoxic $A\beta_{1-42}$ peptide in neuronal cells [74]. *In vivo*, SFN ameliorated cognitive impairment in an acute mouse model of Alzheimer disease (AD) [75]. In Parkinson disease (PD), SFN protected dopaminergic cells against the cytotoxic effects of 6-hydroxydopamine [76]. In the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of PD, SFN counteracted astrogliosis and microgliosis and reduced the death of dopaminergic neurons [77–79]. To improve the stability of SFN, Evgen Pharma has developed a cyclodextrin formulation, SFX-01, which is under phase II clinical trial for the treatment of subarachnoid haemorrhage. A hybrid molecule of SFN and melatonin (ITH12674) was designed to have a dual “drug-prodrug” mechanism of action for the treatment of brain ischemia [80].

Another natural compound that modifies Cys-151 in KEAP1 and has also ROS-scavenging activity is curcumin, a linear diarylheptanoid present in turmeric (*Curcuma longa*) [81]. It has been used for the treatment of obesity, metabolic syndrome, and prediabetes [82–84]. Furthermore, curcumin has been shown to suppress the deleterious action of carcinogens by activating NRF2 [85, 86].

9-Nitro-octadec-9-enoic acid (OA-NO₂) is a nitro-fatty acid with anti-inflammatory properties. OA-NO₂ reacts with several cysteine residues of KEAP1, but mainly with Cys-273 and Cys-288, and its activity seems to be independent of Cys-151 [36]. CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is an isomer of OA-NO₂ which has proven efficacy the uni-nephrectomized deoxycorticosterone acetate-high salt mouse model of CKD [87] and is under several phase I clinical trials for the treatment of this disease [88] and under phase II trials for the treatment of pulmonary arterial hypertension and primary focal segmental glomerulosclerosis.

The list of electrophilic compounds able to interact with KEAP1 is continuously growing. For instance, some compounds like 15-deoxy- $\Delta^{12,14}$ -prostaglandin J₂ interact with Cys-273 and Cys-288 of the KEAP1 homodimer [40]. This prostaglandin has a cyclopentenone core that is able to modify covalently Cys-273 and induce NRF2 in models of ureteral obstruction [89], hepatic ischemia-reperfusion injury [90], and atherosclerosis [91]. However, its clinical use is still far from being demonstrated. In a recent study, the metabolite itaconate was described as a NRF2 activator that alkylates cysteines 151, 257, 288, 273, and 297 of KEAP1. A cell-permeable itaconate derivate, 4-octyl itaconate, protects against lipopolysaccharide cytotoxicity, thus providing an anti-inflammatory response. Furthermore, this compound is a more potent NRF2 activator than DMF [92]. Some

other examples are *tert*-butylhydroquinone [93], diethyl maleate [94], TFM-735 [95], and nitric oxide [96]. However, most of these compounds have not evolved beyond proof-of-concept experiments, and a long way needs to be covered to characterize their pharmacodynamic properties, clinical safety profile, and efficacy in noncommunicable diseases.

3.2. Protein-Protein Interaction Inhibitors of the KEAP1-NRF2 System. Protein-protein interaction (PPI) inhibitors interfere with the docking of NRF2 to the Kelch propeller of KEAP1 and provide more selectivity over electrophilic compounds which may eventually form adducts with redox-sensitive cysteines other than those in KEAP1 [97]. Based on the X-ray crystal structure of KEAP1 [98], small PPI inhibitors have been designed to impede the binding of the ETGE motif to KEAP1 [99]. The ETGE motif adopts a β -hairpin structure that docks to the Kelch propeller of KEAP1 through specific hydrophobic and electrostatic interactions [98, 99]. A similar strategy is devised to prevent the interaction of the low-affinity DLG motif which is required for correct lysine ubiquitination in NRF2 [13].

The first PPI inhibitors of KEAP1 were designed from a series of truncated NRF2 peptides [100, 101]. Some selected peptides are shown in Table 2. It was found that the minimal binding sequence of NRF2 required for docking to KEAP1 is the 9-mer sequence LDEETGEFL [100–102]. A related peptide was designed to increase cell penetrance by adding the Tat sequence of the human immunodeficiency virus and the cleavage sequence of calpain (-Cal-Tat). This peptide demonstrated neuroprotection and cognition-preserving effects in a mouse model of cerebral ischemia [103]. Moreover, hybrid peptides based on both the region of interaction between KEAP1 and NRF2 (ETGE motif) and with the region of interaction between KEAP1 and p62/Sequestosome-1 (SQSTM1) exhibited superior binding activity compared to either native peptide alone [104]. Due to unfavorable drug-like properties, such as low oral bioavailability and cellular permeability of peptides, research has been lately focused on the development of small molecules. However, a cyclic peptide was used recently to improve KEAP1 binding and NRF2 accumulation in cells [105].

Current PPI inhibitors are tetrahydroisoquinoline [97, 106], thiopyrimidine [107], naphthalene [108], carbazole [109], and urea derivatives [110]. Recently, the naphthalene-based nonelectrophilic PPI inhibitors were modified to develop nonnaphthalene heterocyclic scaffold based on 1,4-isoquinoline that avoids the carcinogenic and mutagenic properties of naphthalenes [111]. Some patents addressing these small molecules are presented in Table 3.

Several PPI inhibitors with improved selectivity over electrophiles have been identified through screening of small molecule libraries. These compounds include SRS-5, benzenesulfonyl-pyrimidone 2, N-phenyl-benzenesulfonamide, and a series of 1,4-diphenyl-1,2,3-triazole [106, 112–115]. Recently, a new protocol for identifying reversible modifiers of the NRF2/KEAP1 interaction was proposed [116]. The biochemical assays comprised time-resolved fluorescence resonance energy transfer as primary screening tool, surface plasmon resonance to evaluate the affinity of KEAP1

TABLE 2: Selected peptides acting as NRF2-KEAP1 protein-protein interaction inhibitors.

Sequence	Mechanism of action	Reference
LDEETGEFL-NH ₂		[100, 101]
DEETGE-CAL-Tat (NH ₂ -RKKRRQRRR-PLFAERLDEETGEFLPNH ₂)		[103]
Ac-DPETGEL-OH		[102]
FITC- β -DEETGEF-OH		[102]
FITC- β -LDEETGEFL-OH		[102]
Ac-DEETGEF-OH		[102]
Ac-DPETGEL-OH	Binding to KEAP1-Kelch domain	[102]
FITC-LDEETGEFL-NH ₂		[100]
FAM-LDEETGEFL-NH ₂		[108]
LQLDEETGEFLPIQGK(MR121)-OH		[107]
Ac-LDEETGEFL-NH ₂		[100, 101]
Ac-DPETGEL-NH ₂		[104]
Ac-NPETGEL-OH		[104]
St-DPETGEL-OH		[104]
YGRKKRRQRRRLQLDEETGEFLPIQ		[162]
c[GQLDPETGEFL]		[105]

binders, and ¹H-¹⁵N heteronuclear single-quantum coherence nuclear magnetic resonance assay to further analyze the binding mode. This protocol will help in identifying and improving the properties of reversible binders to KEAP1.

3.3. Other Mechanism of NRF2 Activation. The phosphorylation of NRF2 by GSK-3 leads to its ubiquitination by the E3 ligase β -TrCP and subsequent proteasomal degradation. An aberrant activity of GSK-3 is linked with several pathologies such as AD, cardiovascular diseases, or cancer among others [117–120]. Therefore, several clinical trials are now focused on GSK-3 inhibitors for the treatment of several pathologies [121]. For instance, the GSK-3-inhibitor Tideglusib, a thiazolidinone compound, was studied in phase II trials for AD in the ARGO study [122]. Another inhibitor is Enzastaurin which is intended for the treatment of solid and hematological cancers. Although Enzastaurin provided promising results at the preclinical level, treatment failed in phase II and III trials [123, 124]. GSK-3-dependent NRF2 phosphorylation was shown to be inhibited by nordihydroguaiaretic acid [125]. This compound and its derivative terameprocol are in phase I and II clinical trials for the treatment of several types of cancers, such as gliomas and leukemias (Table 4) [126].

Focusing on E3 ubiquitin ligase β -TrCP, it would be possible to develop small molecules able to disrupt the docking of NRF2 to β -TrCP, hence opening a new way regarding KEAP1-independent activators of NRF2 [127]. A novel E3 ubiquitin ligase linked to KEAP1-independent NRF2 degradation is HRD1 [21]. HRD1-dependent NRF2 degradation has been described in the context of cirrhotic liver. HRD1 is a transcriptional target of X-box-binding protein 1 (XBP1) that is upregulated upon activation of the inositol-requiring

enzyme 1 (IRE1) during endoplasmic reticulum (ER) stress related to cirrhotic conditions. Inhibitors of HRD1 and IRE1 restore the NRF2 response in liver cirrhosis [21].

Several proteins contain a (E/S)TGE motif that resembles the high-affinity ETGE motif of NRF2. The motif confers to these proteins the ability to compete with NRF2 for KEAP1 binding, leading to a noncanonical mechanism of NRF2 stabilization [128]. Proteins containing the (E/S)TGE motif are dipeptidyl peptidase 3, Partner and Localizer of BRCA2, and SQSTM1/p62. SQSTM1/p62, a protein that transports specific cargos to the autophagosome, including KEAP1, sustains NRF2 stabilization and translocation to the nucleus [129–131]. Compounds which elevate SQSTM1/p62 levels, like rapamycin [132] and trehalose [133], are being therefore studied in several phase II and III trials in connection with diabetes mellitus, systemic lupus erythematosus, and autosomal dominant polycystic kidney disease.

Another way to inhibit the transcriptional activity of NRF2 is to impede its interaction with critical components in the nucleus. BTB domain and CNC homolog 1 (BACH1) is a transcriptional repressor which belongs to the cap'n' collar, b-Zip family. BACH1 competes in the nucleus with NRF2 to form heterodimers with small MAF proteins and blocks therefore the expression of ARE genes [134]. A recent study characterized the HPP-4382 compound as an inhibitor of BACH1 repression activity *in vitro* [135].

All these alternative mechanisms for NRF2 stabilization and activation suggest that a combinatorial pharmaceutical approach will be the best way to activate the cytoprotective responses mediated by NRF2.

4. Pharmacologic Inhibitors of NRF2

The implication of NRF2 in cancer is still controversial. Several studies described that NRF2 knockout mice are more susceptible to chemically induced carcinogenesis, pointing NRF2 as a potential tumor suppressor that limits carcinogenesis [136, 137]. On the other hand, NRF2 is overexpressed in many types of tumors, and it has been related to poor disease prognosis because it confers a survival and growth advantage to cancer cells, along with resistance to chemo- and radiotherapy [138–140]. Altogether, these results suggest a protective role of NRF2 in the first steps of cancer, but in advanced stages, NRF2 overexpression helps cancer cells to adapt to the tumorigenic demands. Cancer cells are “addicted” to NRF2 and resist treatment with chemotherapy or radiotherapy [141, 142]. Therefore, it is reasonable to assume that NRF2 inhibitors should sensitize tumor cells to anticancer therapies. In all cases, the mechanism of inhibition is either unknown or not specific, and therefore, NRF2 inhibitors are still far from being translated from bench to bedside.

4.1. Agonists of Nuclear Receptors. Ligands of the glucocorticoid receptor such as dexamethasone [143] and clobetasol propionate [144] inhibit NRF2 by blocking its transcriptional activity or preventing its nuclear translocation. All-*trans*-retinoic acid and bexarotene, agonists of the retinoic acid receptor- α and retinoid X receptor- α , inhibit the transcriptional activity of NRF2 [145, 146]. Retinoid X receptor- α

TABLE 3: Selected small molecule activators of NRF2 acting as NRF2-KEAP1 protein-protein interaction inhibitors.

Compound	Type	Ref.	Patent
(SRS)-5	1,2,3,4-Tetrahydroisoquinoline core	[112]	WO2013/067036
Cpd 15	Benzenesulfonyl-pyrimidone	[107]	WO2016/202253
Cpd 16	1,4-Diaminonaphthalene core	[107]	WO2016/202253
Compound 2	1,4-Diaminonaphthalene core	[163]	CN105566241A
3-(Pyridin-3-ylsulfonyl)-5-(trifluoromethyl)-2H-chromen-2-one (PSTC)	Sulfonyl coumarins	[164]	WO2015/092713
AN-465/144580	Other structure classes	[165]	JP2011/0167537
Compound 7	Arylcyclohexyl pyrazoles	[166]	WO2017060855

appears to bind to the Neh7 domain of NRF2 preventing binding to the ARE enhancer [146]. The pharmacological value of this mechanism of NRF2 inhibition is limited by the multiple effects that are expected through the regulation of these nuclear receptors.

4.2. Natural Compounds. Several compounds of natural origin have been reported to inhibit NRF2. The quassinoid brusatol, extracted from *Brucea javanica*, inhibits the NRF2 transcriptional signature and sensitizes tumors and cancer

cell lines to several chemotherapeutics [147]. However, its mechanism of action is not specific as it blocks protein translation, hence affecting other short-lived proteins as well [148–150].

The flavonoids luteolin [151] and wogonin [152] were reported to inhibit NRF2 and sensitize cells to anticancer drugs by increasing the instability to its transcript. However, later studies also indicated that these compounds may elicit NRF2 activation [153]. Therefore, their value as NRF2 inhibitor is highly controversial.

TABLE 4: Selected KEAP1-independent activators of NRF2.

Compound	Mechanism of action	Disease	Clinical trial	ClinicalTrials.gov identifier
Tideglusib	GSK-3 inhibition	Autism spectrum disorders	Phase II	NCT02586935
		Myotonic dystrophy 1	Phase II	NCT02858908
		Alzheimer's disease	Phase II	NCT01350362
Nordihydroguaiaretic acid (NDGA)	GSK-3 inhibition	Prostate cancer	Phase II	NCT00678015
		Brain and central nervous system tumors	Phase I	NCT00313534
Terameprocol (NDGA derivative)	GSK-3 inhibition	High-grade glioma	Phase I	NCT02575794
		Leukemias		
		Acute myeloid leukemia (AML)	Phase I	NCT00664677
		Acute lymphocytic leukemia (ALL)		
		Refractory solid tumors		
		Lymphoma	Phase I	NCT00664586
Enzastaurin	GSK-3 inhibition	Diffuse large B cell lymphoma	Phase III	NCT03263026
		Solid tumor Lymphoma, malignant	Phase I	NCT01432951
LS-102	HRD1 inhibition	—	—	No clinical trials available
Rapamycin	p62/SQSTM1 activation	Diabetes mellitus, type 1	Phase III	NCT01060605
		Systemic lupus erythematosus (SLE)	Phase II	NCT00779194
		Autosomal dominant polycystic kidney disease	Phase II/III	NCT00920309

TABLE 4: Continued.

Compound	Mechanism of action	Disease	Clinical trial	ClinicalTrials.gov identifier
<p>HPP-4382</p>	BACH1 inhibition	—	—	No clinical trials available

Other natural compounds such the mycotoxin ochratoxin A [154] and the coffee alkaloid trigonelline [155] prevent the nuclear translocation of NRF2. In leukemic cells, malabaricone-A, a plant-derived prooxidant, effectively inhibits NRF2 transcriptional activity as reflected by a reduction in HO-1 protein levels and leads to ROS accumulation and subsequent cell apoptosis [156]. Ascorbic acid, a well-known ROS scavenger, was found to sensitize imatinib-resistant cancer cells by decreasing the levels of the NRF2/ARE complex, hence reducing the expression of Glutamate-Cysteine Ligase Catalytic Subunit and dropping GSH levels [157]. In general, the main concern with these compounds is that their selectivity for NRF2 inhibition has not been conclusively demonstrated.

4.3. Other Approaches. The lack of knowledge about the fine structure of NRF2 hampers a straightforward strategy for the *in silico* analysis of small molecules that might dock to relevant domains of interaction with MAF proteins, ARE enhancer, etc. Therefore, a high-throughput screening was used which is helping in the identification of NRF2 inhibitors but still not providing selectivity [158]. A first-in-class compound, termed ML385, was found after the screening of a chemical library of 400,000 molecules. ML385 blocks NRF2 transcriptional activity and sensitizes KEAP1-deficient cells to carboplatin and other chemotherapeutics. ML385 interacts with the DNA-binding domain of NRF2 and most likely prevents the binding of NRF2 to AREs. However, given the similarity between AREs and other enhancers such as AP1, additional studies are needed to clearly establish if ML385 is selective for NRF2 or if it also inhibits other bZip transcription factors involved in chemoresistance.

Halofuginone, a synthetic derivative of febrifugine that is used in veterinary medicine, blocked the chemoresistance and radioresistance of cancer cells in parallel to the decrease of NRF2 protein levels [159]. It was found that halofuginone induces amino acid starvation resulting in global inhibition of protein synthesis.

Another compound, AEM1, decreased the expression of NRF2-controlled genes and sensitized KEAP1-deficient A549 lung tumor cells to various chemotherapeutic agents [160]. Although it seems that the anticancer effect of AEM1 is restricted to cell lines harboring mutations which render NRF2 constitutively active, the selectivity for NRF2 inhibition is not demonstrated yet.

In HeLa cells transfected with an ARE-driven luciferase reporter, a pyrazolyl hydroxamic acid, termed 4f, inhibited

NRF2, reduced cell proliferation of myeloid cell lines, and increased apoptosis of acute myeloid leukemia cells [161]. Most likely, 4f altered the BCL2/BAX ratio and induced mitochondria-dependent apoptosis.

5. Conclusions

The NRF2/KEAP1 system represents a very promising pharmacological target to control common pathologic mechanisms of many chronic diseases characterized by low-grade oxidative stress and inflammation. A plethora of NRF2 activators, mostly of electrophilic nature, have been identified and a few are under clinical development. The pleiotropic effects of NRF2 on cell physiology together with potential off-target effects exerted by some NRF2 activators explain why drug development is moving slowly. The field of NRF2 inhibitors that may have a huge impact on cancer therapy is less advanced. Future work should be directed towards finding compounds with a good pharmacokinetic/pharmacodynamic profile for specific diseases.

Abbreviations

AD:	Alzheimer's disease
AHR:	Aryl hydrocarbon receptor
BACH1:	BTB domain and CNC homolog 1
BTB:	Bric-a-brac, tramtrack, broad complex
β-TrCP:	Beta-transducin repeat-containing E3 ubiquitin protein ligase
CUL3:	Cullin3
DMF:	Dimethyl fumarate
DRG:	Double glycine repeat
GSH:	Glutathione
GSK-3:	Glycogen synthase kinase
IVR:	Intervening region
KEAP1:	Kelch-like ECH-associated protein 1
MMF:	Monomethyl fumarate
MS:	Multiple sclerosis
<i>NFE2L2</i> :	Gene encoding NRF2
NRF2:	Nuclear factor erythroid 2-related factor 2
PD:	Parkinson's disease
PPI:	Protein-protein interaction
RBX1:	RING-box protein 1
ROS:	Reactive oxygen species
SNF:	Sulforaphane
SQSTM1:	Sequestosome-1
XRE:	Xenobiotic response element.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Acknowledgments

This work was supported by grants SAF2016-76520-R of the Spanish Ministry of Economy and Competitiveness, B2017/BMD-3827 of the Autonomous Community of Madrid, and P_37_732/2016 REDBRAIN of the European Regional Development Fund; Competitiveness Operational Program 2014-2020. NRA and RFG are recipients of FPU and FPI contracts, respectively, of the Spanish Ministry of Economy and Competitiveness.

Supplementary Materials

Overview of the strategies aimed at pharmacologic regulation of NRF2. KEAP1-dependent and KEAP1-independent strategies to activate NRF2 are included in red boxes. The current strategies for inhibition of NRF2 are indicated in the grey boxes. PPI: protein-protein interaction inhibitor; DPI: DNA-protein interaction inhibitor. (*Supplementary Materials*)

References

- [1] Q. Ma, "Role of nrf2 in oxidative stress and toxicity," *Annual Review of Pharmacology and Toxicology*, vol. 53, no. 1, pp. 401–426, 2013.
- [2] J. D. Hayes and A. T. Dinkova-Kostova, "The Nrf2 regulatory network provides an interface between redox and intermediary metabolism," *Trends in Biochemical Sciences*, vol. 39, no. 4, pp. 199–218, 2014.
- [3] M. Pajares, N. Jiménez-Moreno, Á. J. García-Yagüe et al., "Transcription factor NFE2L2/NRF2 is a regulator of macroautophagy genes," *Autophagy*, vol. 12, no. 10, pp. 1902–1916, 2016.
- [4] M. Pajares, A. Cuadrado, and A. I. Rojo, "Modulation of proteostasis by transcription factor NRF2 and impact in neurodegenerative diseases," *Redox Biology*, vol. 11, pp. 543–553, 2017.
- [5] M. R. de la Vega, M. Dodson, C. Gross et al., "Role of Nrf2 and autophagy in acute lung injury," *Current Pharmacology Reports*, vol. 2, no. 2, pp. 91–101, 2016.
- [6] M. Pajares, N. Jiménez-Moreno, I. H. K. Dias et al., "Redox control of protein degradation," *Redox Biology*, vol. 6, pp. 409–420, 2015.
- [7] A. Cuadrado, A. I. Rojo, G. Wells et al., "Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases," *Nature Reviews Drug Discovery*, vol. 18, no. 4, pp. 295–317, 2019.
- [8] A. Cuadrado, G. Manda, A. Hassan et al., "Transcription factor NRF2 as a therapeutic target for chronic diseases: a systems medicine approach," *Pharmacological Reviews*, vol. 70, no. 2, pp. 348–383, 2018.
- [9] M. Rojo de la Vega, E. Chapman, and D. D. Zhang, "NRF2 and the hallmarks of cancer," *Cancer Cell*, vol. 34, no. 1, pp. 21–43, 2018.
- [10] M. McMahon, N. Thomas, K. Itoh, M. Yamamoto, and J. D. Hayes, "Redox-regulated turnover of Nrf2 is determined by at least two separate protein domains, the redox-sensitive Neh2 degron and the redox-insensitive Neh6 degron," *Journal of Biological Chemistry*, vol. 279, no. 30, pp. 31556–31567, 2004.
- [11] Y. Katoh, K. Iida, M. I. Kang et al., "Evolutionary conserved N-terminal domain of Nrf2 is essential for the Keap1-mediated degradation of the protein by proteasome," *Archives of Biochemistry and Biophysics*, vol. 433, no. 2, pp. 342–350, 2005.
- [12] K. I. Tong, Y. Katoh, H. Kusunoki, K. Itoh, T. Tanaka, and M. Yamamoto, "Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model," *Molecular and Cellular Biology*, vol. 26, no. 8, pp. 2887–2900, 2006.
- [13] K. I. Tong, B. Padmanabhan, A. Kobayashi et al., "Different electrostatic potentials define ETGE and DLG motifs as hinge and latch in oxidative stress response," *Molecular and Cellular Biology*, vol. 27, no. 21, pp. 7511–7521, 2007.
- [14] T. Suzuki, H. Motohashi, and M. Yamamoto, "Toward clinical application of the Keap1-Nrf2 pathway," *Trends in Pharmacological Sciences*, vol. 34, no. 6, pp. 340–346, 2013.
- [15] V. Sihvola and A. L. Levonen, "Keap1 as the redox sensor of the antioxidant response," *Archives of Biochemistry and Biophysics*, vol. 617, pp. 94–100, 2017.
- [16] R. Holland, A. E. Hawkins, A. L. Eggler, A. D. Mesecar, D. Fabris, and J. C. Fishbein, "Prospective type 1 and type 2 disulfides of Keap1 protein," *Chemical Research in Toxicology*, vol. 21, no. 10, pp. 2051–2060, 2008.
- [17] E. M. Hur and F. Q. Zhou, "GSK3 signalling in neural development," *Nature Reviews Neuroscience*, vol. 11, no. 8, pp. 539–551, 2010.
- [18] K. P. Hoefflich, J. Luo, E. A. Rubie, M. S. Tsao, O. Jin, and J. R. Woodgett, "Requirement for glycogen synthase kinase-3 β in cell survival and NF- κ B activation," *Nature*, vol. 406, no. 6791, pp. 86–90, 2000.
- [19] A. Cuadrado, "Structural and functional characterization of Nrf2 degradation by glycogen synthase kinase 3/ β -TrCP," *Free Radical Biology & Medicine*, vol. 88, pp. 147–157, 2015.
- [20] S. Chowdhry, Y. Zhang, M. McMahon, C. Sutherland, A. Cuadrado, and J. D. Hayes, "Nrf2 is controlled by two distinct β -TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity," *Oncogene*, vol. 32, no. 32, pp. 3765–3781, 2013.
- [21] T. Wu, F. Zhao, B. Gao et al., "Hrd1 suppresses Nrf2-mediated cellular protection during liver cirrhosis," *Genes & Development*, vol. 28, no. 7, pp. 708–722, 2014.
- [22] W. Miao, L. Hu, P. J. Scrivens, and G. Batist, "Transcriptional regulation of NF-E2 p45-related factor (NRF2) expression by the aryl hydrocarbon receptor-xenobiotic response element signaling pathway: direct cross-talk between phase I and II drug-metabolizing enzymes," *Journal of Biological Chemistry*, vol. 280, no. 21, pp. 20340–20348, 2005.
- [23] M. K. Kwak, K. Itoh, M. Yamamoto, and T. W. Kensler, "Enhanced expression of the transcription factor Nrf2 by cancer chemopreventive agents: role of antioxidant response element-like sequences in the nrf2 promoter," *Molecular and Cellular Biology*, vol. 22, no. 9, pp. 2883–2892, 2002.
- [24] S. Tao, S. Wang, S. J. Moghaddam et al., "Oncogenic KRAS confers chemoresistance by upregulating NRF2," *Cancer Research*, vol. 74, no. 24, pp. 7430–7441, 2014.

- [25] G. M. DeNicola, F. A. Karreth, T. J. Humpton et al., "Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis," *Nature*, vol. 475, no. 7354, pp. 106–109, 2011.
- [26] S. A. Rushworth, L. Zaitseva, M. Y. Murray, N. M. Shah, K. M. Bowles, and D. J. MacEwan, "The high Nrf2 expression in human acute myeloid leukemia is driven by NF- κ B and underlies its chemo-resistance," *Blood*, vol. 120, no. 26, pp. 5188–5198, 2012.
- [27] C. Sangokoya, M. J. Telen, and J. T. Chi, "microRNA miR-144 modulates oxidative stress tolerance and associates with anemia severity in sickle cell disease," *Blood*, vol. 116, no. 20, pp. 4338–4348, 2010.
- [28] M. Yang, Y. Yao, G. Eades, Y. Zhang, and Q. Zhou, "MiR-28 regulates Nrf2 expression through a Keap1-independent mechanism," *Breast Cancer Research and Treatment*, vol. 129, no. 3, pp. 983–991, 2011.
- [29] X. Sun, X. Li, S. Ma, Y. Guo, and Y. Li, "MicroRNA-98-5p ameliorates oxygen-glucose deprivation/reoxygenation (OGD/R)-induced neuronal injury by inhibiting Bach1 and promoting Nrf2/ARE signaling," *Biochemical and Biophysical Research Communications*, vol. 507, no. 1–4, pp. 114–121, 2018.
- [30] F. P. Fabrizio, A. Sparaneo, D. Trombetta, and L. A. Muscarella, "Epigenetic versus genetic deregulation of the KEAP1/NRF2 axis in solid tumors: focus on methylation and noncoding RNAs," *Oxidative Medicine and Cellular Longevity*, vol. 2018, Article ID 2492063, 21 pages, 2018.
- [31] S. Magesh, Y. Chen, and L. Hu, "Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents," *Medicinal Research Reviews*, vol. 32, no. 4, pp. 687–726, 2012.
- [32] W. Hur and N. S. Gray, "Small molecule modulators of anti-oxidant response pathway," *Current Opinion in Chemical Biology*, vol. 15, no. 1, pp. 162–173, 2011.
- [33] T. Satoh, S. R. McKercher, and S. A. Lipton, "Nrf2/ARE-mediated antioxidant actions of pro-electrophilic drugs," *Free Radical Biology & Medicine*, vol. 65, pp. 645–657, 2013.
- [34] A. J. Wilson, J. K. Kerns, J. F. Callahan, and C. J. Moody, "Keap calm, and carry on covalently," *Journal of Medicinal Chemistry*, vol. 56, no. 19, pp. 7463–7476, 2013.
- [35] M. H. L. Wong, H. K. Bryan, I. M. Copple et al., "Design and synthesis of irreversible analogues of bardoxolone methyl for the identification of pharmacologically relevant targets and interaction sites," *Journal of Medicinal Chemistry*, vol. 59, no. 6, pp. 2396–2409, 2016.
- [36] E. Kansanen, G. Bonacci, F. J. Schopfer et al., "Electrophilic nitro-fatty acids activate NRF2 by a KEAP1 cysteine 151-independent mechanism," *Journal of Biological Chemistry*, vol. 286, no. 16, pp. 14019–14027, 2011.
- [37] S. Fourquet, R. Guerois, D. Biard, and M. B. Toledano, "Activation of NRF2 by nitrosative agents and H₂O₂ involves KEAP1 disulfide formation," *Journal of Biological Chemistry*, vol. 285, no. 11, pp. 8463–8471, 2010.
- [38] A. L. Levonen, A. Landar, A. Ramachandran et al., "Cellular mechanisms of redox cell signalling: role of cysteine modification in controlling antioxidant defences in response to electrophilic lipid oxidation products," *Biochemical Journal*, vol. 378, no. 2, pp. 373–382, 2004.
- [39] N. Wakabayashi, A. T. Dinkova-Kostova, W. D. Holtzclaw et al., "Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 101, no. 7, pp. 2040–2045, 2004.
- [40] T. Yamamoto, T. Suzuki, A. Kobayashi et al., "Physiological significance of reactive cysteine residues of Keap1 in determining Nrf2 activity," *Molecular and Cellular Biology*, vol. 28, no. 8, pp. 2758–2770, 2008.
- [41] R. Saito, T. Suzuki, K. Hiramoto et al., "Characterizations of three major cysteine sensors of Keap1 in stress response," *Molecular and Cellular Biology*, vol. 36, no. 2, article MCB.00868-15, 2015.
- [42] L. Baird, D. Lleres, S. Swift, and A. T. Dinkova-Kostova, "Regulatory flexibility in the Nrf2-mediated stress response is conferred by conformational cycling of the Keap1-Nrf2 protein complex," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 110, no. 38, pp. 15259–15264, 2013.
- [43] A. Cleasby, J. Yon, P. J. Day et al., "Structure of the BTB domain of Keap1 and its interaction with the triterpenoid antagonist CDDO," *PLoS One*, vol. 9, no. 6, article e98896, 2014.
- [44] T. Iso, T. Suzuki, L. Baird, and M. Yamamoto, "Absolute amounts and status of the Nrf2-Keap1-Cul3 complex within cells," *Molecular and Cellular Biology*, vol. 36, no. 24, pp. 3100–3112, 2016.
- [45] S. Dayalan Naidu, A. Muramatsu, R. Saito et al., "C151 in KEAP1 is the main cysteine sensor for the cyanoenone class of NRF2 activators, irrespective of molecular size or shape," *Scientific Reports*, vol. 8, no. 1, p. 8037, 2018.
- [46] A. T. Dinkova-Kostova, K. T. Liby, K. K. Stephenson et al., "Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 102, no. 12, pp. 4584–4589, 2005.
- [47] K. T. Liby and M. B. Sporn, "Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease," *Pharmacological Reviews*, vol. 64, no. 4, pp. 972–1003, 2012.
- [48] P. E. Pergola, P. Raskin, R. D. Toto et al., "Bardoxolone methyl and kidney function in CKD with type 2 diabetes," *The New England Journal of Medicine*, vol. 365, no. 4, pp. 327–336, 2011.
- [49] D. D. Zhang, "Bardoxolone brings Nrf2-based therapies to light," *Antioxidants & Redox Signaling*, vol. 19, no. 5, pp. 517–518, 2013.
- [50] D. R. Lynch, J. Farmer, L. Hauser et al., "Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia," *Annals of Clinical Translational Neurology*, vol. 6, no. 1, pp. 15–26, 2019.
- [51] P. S. Rabbani, T. Ellison, B. Waqas et al., "Targeted Nrf2 activation therapy with RTA 408 enhances regenerative capacity of diabetic wounds," *Diabetes Research and Clinical Practice*, vol. 139, pp. 11–23, 2018.
- [52] Z. Xu, F. Zhang, F. Sun, K. F. Gu, S. Dong, and D. He, "Dimethyl fumarate for multiple sclerosis," *Cochrane Database of Systematic Reviews*, vol. 4, article CD011076, 2015.
- [53] S. Schimrigk, N. Brune, K. Hellwig et al., "Oral fumaric acid esters for the treatment of active multiple sclerosis: an

- open-label, baseline-controlled pilot study,” *European Journal of Neurology*, vol. 13, no. 6, pp. 604–610, 2006.
- [54] R. Gold, L. Kappos, D. L. Arnold et al., “Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis,” *The New England Journal of Medicine*, vol. 367, no. 12, pp. 1098–1107, 2012.
 - [55] R. J. Fox, D. H. Miller, J. T. Phillips et al., “Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis,” *The New England Journal of Medicine*, vol. 367, no. 12, pp. 1087–1097, 2012.
 - [56] S. Hoxtermann, C. Nuchel, and P. Altmeyer, “Fumaric acid esters suppress peripheral CD4- and CD8-positive lymphocytes in psoriasis,” *Dermatology*, vol. 196, no. 2, pp. 223–230, 1998.
 - [57] E. A. Mills, M. A. Ogrodnik, A. Plave, and Y. Mao-Draayer, “Emerging understanding of the mechanism of action for dimethyl fumarate in the treatment of multiple sclerosis,” *Frontiers in Neurology*, vol. 9, no. 5, 2018.
 - [58] M. Ghadiri, A. Rezk, R. Li et al., “Dimethyl fumarate-induced lymphopenia in MS due to differential T-cell subset apoptosis,” *Neurology - Neuroimmunology Neuroinflammation*, vol. 4, no. 3, article e340, 2017.
 - [59] R. Li, A. Rezk, M. Ghadiri et al., “Dimethyl fumarate treatment mediates an anti-inflammatory shift in B cell subsets of patients with multiple sclerosis,” *Journal of Immunology*, vol. 198, no. 2, pp. 691–698, 2017.
 - [60] M. D. Smith, K. A. Martin, P. A. Calabresi, and P. Bhargava, “Dimethyl fumarate alters B-cell memory and cytokine production in MS patients,” *Annals of Clinical Translational Neurology*, vol. 4, no. 5, pp. 351–355, 2017.
 - [61] R. A. Linker, D. H. Lee, S. Ryan et al., “Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway,” *Brain*, vol. 134, no. 3, pp. 678–692, 2011.
 - [62] S. Dibbert, B. Clement, T. Skak-Nielsen, U. Mrowietz, and M. Rostami-Yazdi, “Detection of fumarate-glutathione adducts in the portal vein blood of rats: evidence for rapid dimethylfumarate metabolism,” *Archives of Dermatological Research*, vol. 305, no. 5, pp. 447–451, 2013.
 - [63] H. Sun, J. Zhu, H. Lin, K. Gu, and F. Feng, “Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016),” *Expert Opinion on Therapeutic Patents*, vol. 27, no. 7, pp. 763–785, 2017.
 - [64] T. A. Zeidan, S. Duncan, C. P. Hencken, T. A. Wynn, and C. N. Sanrame, *Prodrugs of fumarates and their use in treating various diseases*, Alkermes Pharma Ireland Limited, 2014.
 - [65] F. von Glehn, R. P. C. Dias-Carneiro, A. S. Moraes et al., “Dimethyl fumarate downregulates the immune response through the HCA2/GPR109A pathway: implications for the treatment of multiple sclerosis,” *Multiple Sclerosis and Related Disorders*, vol. 23, pp. 46–50, 2018.
 - [66] T. W. Kensler, G. S. Qian, J. G. Chen, and J. D. Groopman, “Translational strategies for cancer prevention in liver,” *Nature Reviews Cancer*, vol. 3, no. 5, pp. 321–329, 2003.
 - [67] K. Okada, J. Shoda, K. Taguchi et al., “Ursodeoxycholic acid stimulates Nrf2-mediated hepatocellular transport, detoxification, and antioxidative stress systems in mice,” *American Journal of Physiology-Gastrointestinal and Liver Physiology*, vol. 295, no. 4, pp. G735–G747, 2008.
 - [68] K. Kawata, Y. Kobayashi, K. Souda et al., “Enhanced hepatic Nrf2 activation after ursodeoxycholic acid treatment in patients with primary biliary cirrhosis,” *Antioxidants & Redox Signaling*, vol. 13, no. 3, pp. 259–268, 2010.
 - [69] D. P. W. Wong, M. Y. Ng, J. Y. Leung et al., “Regulation of the NRF2 transcription factor by andrographolide and organic extracts from plant endophytes,” *PLoS One*, vol. 13, no. 10, article e0204853, 2018.
 - [70] Z. Bahadoran, P. Mirmiran, F. Hosseiniapanah, A. Rajab, G. Asghari, and F. Azizi, “Broccoli sprouts powder could improve serum triglyceride and oxidized LDL/LDL-cholesterol ratio in type 2 diabetic patients: a randomized double-blind placebo-controlled clinical trial,” *Diabetes Research and Clinical Practice*, vol. 96, no. 3, pp. 348–354, 2012.
 - [71] A. S. Axelsson, E. Tubbs, B. Mecham et al., “Sulforaphane reduces hepatic glucose production and improves glucose control in patients with type 2 diabetes,” *Science Translational Medicine*, vol. 9, no. 394, article eaah4477, 2017.
 - [72] Z. Ping, W. Liu, Z. Kang et al., “Sulforaphane protects brains against hypoxic-ischemic injury through induction of Nrf2-dependent phase 2 enzyme,” *Brain Research*, vol. 1343, pp. 178–185, 2010.
 - [73] J. Zhao, N. Kobori, J. Aronowski, and P. K. Dash, “Sulforaphane reduces infarct volume following focal cerebral ischemia in rodents,” *Neuroscience Letters*, vol. 393, no. 2-3, pp. 108–112, 2006.
 - [74] H. M. Park, J. A. Kim, and M. K. Kwak, “Protection against amyloid beta cytotoxicity by sulforaphane: role of the proteasome,” *Archives of Pharmacological Research*, vol. 32, no. 1, pp. 109–115, 2009.
 - [75] H. V. Kim, H. Y. Kim, H. Y. Ehrlich, S. Y. Choi, D. J. Kim, and Y. S. Kim, “Amelioration of Alzheimer’s disease by neuroprotective effect of sulforaphane in animal model,” *Amyloid*, vol. 20, no. 1, pp. 7–12, 2013.
 - [76] J. M. Han, Y. J. Lee, S. Y. Lee et al., “Protective effect of sulforaphane against dopaminergic cell death,” *The Journal of Pharmacology and Experimental Therapeutics*, vol. 321, no. 1, pp. 249–256, 2007.
 - [77] A. Jazwa, A. I. Rojo, N. G. Innamorato, M. Hesse, J. Fernández-Ruiz, and A. Cuadrado, “Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism,” *Antioxidants & Redox Signaling*, vol. 14, no. 12, pp. 2347–2360, 2011.
 - [78] A. Tarozzi, C. Angeloni, M. Malaguti, F. Morroni, S. Hrelia, and P. Hrelia, “Sulforaphane as a potential protective phytochemical against neurodegenerative diseases,” *Oxidative Medicine and Cellular Longevity*, vol. 2013, Article ID 415078, 10 pages, 2013.
 - [79] C. A. Houghton, R. G. Fassett, and J. S. Coombes, “Sulforaphane and other nutrigenomic Nrf2 activators: can the clinician’s expectation be matched by the reality?,” *Oxidative Medicine and Cellular Longevity*, vol. 2016, Article ID 7857186, 17 pages, 2016.
 - [80] J. Egea, I. Buendia, E. Parada et al., “Melatonin-sulforaphane hybrid ITH12674 induces neuroprotection in oxidative stress conditions by a ‘drug-prodrug’ mechanism of action,” *British Journal of Pharmacology*, vol. 172, no. 7, pp. 1807–1821, 2015.
 - [81] Sreejayan and M. N. A. Rao, “Nitric oxide scavenging by curcuminoids,” *The Journal of Pharmacy and Pharmacology*, vol. 49, no. 1, pp. 105–107, 1997.

- [82] P. Qiu, S. Man, J. Li et al., "Overdose intake of curcumin initiates the unbalanced state of bodies," *Journal of Agricultural and Food Chemistry*, vol. 64, no. 13, pp. 2765–2771, 2016.
- [83] L. X. Na, Y. Li, H. Z. Pan et al., "Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial," *Molecular Nutrition & Food Research*, vol. 57, no. 9, pp. 1569–1577, 2013.
- [84] S. Chuengsamarn, S. Rattanamongkolgul, B. Phonrat, R. Tungtrongchitr, and S. Jirawatnotai, "Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial," *The Journal of Nutritional Biochemistry*, vol. 25, no. 2, pp. 144–150, 2014.
- [85] H. Hatcher, R. Planalp, J. Cho, F. M. Torti, and S. V. Torti, "Curcumin: from ancient medicine to current clinical trials," *Cellular and Molecular Life Sciences*, vol. 65, no. 11, pp. 1631–1652, 2008.
- [86] E. Balogun, M. Hoque, P. GONG et al., "Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element," *The Biochemical Journal*, vol. 371, no. 3, pp. 887–895, 2003.
- [87] C. M. Arbeeny, H. Ling, M. M. Smith et al., "CXA-10, a nitrated fatty acid, is renoprotective in deoxycorticosterone acetate-salt nephropathy," *The Journal of Pharmacology and Experimental Therapeutics*, vol. 369, no. 3, pp. 503–510, 2019.
- [88] C. I. Batthyany and G. V. Lopez, *Nitroalkene tocopherols and analogs thereof for use in the treatment and prevention of inflammation related conditions*, Complexa Inc., 2015.
- [89] L. Nilsson, F. Palm, and R. Nørregaard, "15-Deoxy- $\Delta^{12,14}$ -prostaglandin J_2 exerts antioxidant effects while exacerbating inflammation in mice subjected to ureteral obstruction," *Mediators of Inflammation*, vol. 2017, Article ID 3924912, 10 pages, 2017.
- [90] K. Chen, J. J. Li, S. N. Li et al., "15-Deoxy- $\Delta^{12,14}$ -prostaglandin J_2 alleviates hepatic ischemia-reperfusion injury in mice via inducing antioxidant response and inhibiting apoptosis and autophagy," *Acta Pharmacologica Sinica*, vol. 38, no. 5, pp. 672–687, 2017.
- [91] J. Lu, S. Guo, X. Xue et al., "Identification of a novel series of anti-inflammatory and anti-oxidative phospholipid oxidation products containing the cyclopentenone moiety *in vitro* and *in vivo*: implication in atherosclerosis," *Journal of Biological Chemistry*, vol. 292, no. 13, pp. 5378–5391, 2017.
- [92] E. L. Mills, D. G. Ryan, H. A. Prag et al., "Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1," *Nature*, vol. 556, no. 7699, pp. 113–117, 2018.
- [93] X. J. Wang, J. D. Hayes, L. G. Higgins, C. R. Wolf, and A. T. Dinkova-Kostova, "Activation of the NRF2 signaling pathway by copper-mediated redox cycling of para- and ortho-hydroquinones," *Chemistry & Biology*, vol. 17, no. 1, pp. 75–85, 2010.
- [94] J. M. Lee, J. D. Moehlenkamp, J. M. Hanson, and J. A. Johnson, "Nrf2-dependent activation of the antioxidant responsive element by tert-butylhydroquinone is independent of oxidative stress in IMR-32 human neuroblastoma cells," *Biochemical and Biophysical Research Communications*, vol. 280, no. 1, pp. 286–292, 2001.
- [95] C. Higashi, A. Kawaji, N. Tsuda et al., "The novel Nrf2 inducer TFM-735 ameliorates experimental autoimmune encephalomyelitis in mice," *European Journal of Pharmacology*, vol. 802, pp. 76–84, 2017.
- [96] T. Suzuki and M. Yamamoto, "Stress-sensing mechanisms and the physiological roles of the Keap1-Nrf2 system during cellular stress," *Journal of Biological Chemistry*, vol. 292, no. 41, pp. 16817–16824, 2017.
- [97] B. G. Richardson, A. D. Jain, T. E. Speltz, and T. W. Moore, "Non-electrophilic modulators of the canonical Keap1/Nrf2 pathway," *Bioorganic & Medicinal Chemistry Letters*, vol. 25, no. 11, pp. 2261–2268, 2015.
- [98] B. Padmanabhan, K. I. Tong, T. Ohta et al., "Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer," *Molecular Cell*, vol. 21, no. 5, pp. 689–700, 2006.
- [99] S. C. Lo, X. Li, M. T. Henzl, L. J. Beamer, and M. Hannink, "Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling," *The EMBO Journal*, vol. 25, no. 15, pp. 3605–3617, 2006.
- [100] D. Inoyama, Y. Chen, X. Huang, L. J. Beamer, A. N. T. Kong, and L. Hu, "Optimization of fluorescently labeled Nrf2 peptide probes and the development of a fluorescence polarization assay for the discovery of inhibitors of Keap1-Nrf2 interaction," *Journal of Biomolecular Screening*, vol. 17, no. 4, pp. 435–447, 2012.
- [101] Y. Chen, D. Inoyama, A. N. T. Kong, L. J. Beamer, and L. Hu, "Kinetic analyses of Keap1-Nrf2 interaction and determination of the minimal Nrf2 peptide sequence required for Keap1 binding using surface plasmon resonance," *Chemical Biology & Drug Design*, vol. 78, no. 6, pp. 1014–1021, 2011.
- [102] R. Hancock, H. C. Bertrand, T. Tsujita et al., "Peptide inhibitors of the Keap1-Nrf2 protein-protein interaction," *Free Radical Biology & Medicine*, vol. 52, no. 2, pp. 444–451, 2012.
- [103] J. Tu, X. Zhang, Y. Zhu et al., "Cell-permeable peptide targeting the Nrf2-Keap1 interaction: a potential novel therapy for global cerebral ischemia," *The Journal of Neuroscience*, vol. 35, no. 44, pp. 14727–14739, 2015.
- [104] R. Hancock, M. Schaap, H. Pfister, and G. Wells, "Peptide inhibitors of the Keap1-Nrf2 protein-protein interaction with improved binding and cellular activity," *Organic & Biomolecular Chemistry*, vol. 11, no. 21, pp. 3553–3557, 2013.
- [105] M. C. Lu, Q. Jiao, T. Liu et al., "Discovery of a head-to-tail cyclic peptide as the Keap1-Nrf2 protein-protein interaction inhibitor with high cell potency," *European Journal of Medicinal Chemistry*, vol. 143, pp. 1578–1589, 2018.
- [106] E. Jnoff, C. Albrecht, J. J. Barker et al., "Binding mode and structure-activity relationships around direct inhibitors of the Nrf2-Keap1 complex," *ChemMedChem*, vol. 9, no. 4, pp. 699–705, 2014.
- [107] D. Marcotte, W. Zeng, J. C. Hus et al., "Small molecules inhibit the interaction of Nrf2 and the Keap1 Kelch domain through a non-covalent mechanism," *Bioorganic & Medicinal Chemistry*, vol. 21, no. 14, pp. 4011–4019, 2013.
- [108] Z.-Y. Jiang, M. C. Lu, L.-L. Xu et al., "Discovery of potent Keap1-Nrf2 protein-protein interaction inhibitor based on molecular binding determinants analysis," *Journal of Medicinal Chemistry*, vol. 57, no. 6, pp. 2736–2745, 2014.
- [109] N. Ranjan, G. Fulcrand, A. King et al., "Selective inhibition of bacterial topoisomerase I by alkynyl-bisbenzimidazoles," *MedChemComm*, vol. 5, no. 6, pp. 816–825, 2014.
- [110] M. Sato, T. Aoki, H. Inoue et al., "Keap1 protein binding compound, crystal of complex between the same and Keap1 protein, and method for producing the same," TORAY INDUSTRIES Inc., 2013.

- [111] B. G. Richardson, A. D. Jain, H. R. Potteti et al., "Replacement of a naphthalene scaffold in Kelch-like ECH-associated protein 1 (KEAP1)/nuclear factor (erythroid-derived 2)-like 2 (NRF2) inhibitors," *Journal of Medicinal Chemistry*, vol. 61, no. 17, pp. 8029–8047, 2018.
- [112] L. Hu, S. Magesh, L. Chen et al., "Discovery of a small-molecule inhibitor and cellular probe of Keap1-Nrf2 protein-protein interaction," *Bioorganic & Medicinal Chemistry Letters*, vol. 23, no. 10, pp. 3039–3043, 2013.
- [113] X. Wen, G. Thorne, L. Hu, M. S. Joy, and L. M. Aleksunes, "Activation of NRF2 signaling in HEK293 cells by a first-in-class direct KEAP1-NRF2 inhibitor," *Journal of Biochemical and Molecular Toxicology*, vol. 29, no. 6, pp. 261–266, 2015.
- [114] H. C. Bertrand, M. Schaap, L. Baird et al., "Design, synthesis, and evaluation of triazole derivatives that induce Nrf2 dependent gene products and inhibit the Keap1-Nrf2 protein-protein interaction," *Journal of Medicinal Chemistry*, vol. 58, no. 18, pp. 7186–7194, 2015.
- [115] H. R. Nasiri, S. Linge, and D. Ullmann, "Thermodynamic profiling of inhibitors of Nrf2:Keap1 interactions," *Bioorganic & Medicinal Chemistry Letters*, vol. 26, no. 2, pp. 526–529, 2016.
- [116] A. Bresciani, A. Missineo, M. Gallo et al., "Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1)," *Archives of Biochemistry and Biophysics*, vol. 631, pp. 31–41, 2017.
- [117] C. Hooper, R. Killick, and S. Lovestone, "The GSK3 hypothesis of Alzheimer's disease," *Journal of Neurochemistry*, vol. 104, no. 6, pp. 1433–1439, 2008.
- [118] T. Silva, J. Reis, J. Teixeira, and F. Borges, "Alzheimer's disease, enzyme targets and drug discovery struggles: from natural products to drug prototypes," *Ageing Research Reviews*, vol. 15, pp. 116–145, 2014.
- [119] J. Luo, "Glycogen synthase kinase 3 β (GSK3 β) in tumorigenesis and cancer chemotherapy," *Cancer Letters*, vol. 273, no. 2, pp. 194–200, 2009.
- [120] H. Lal, F. Ahmad, J. Woodgett, and T. Force, "The GSK-3 family as therapeutic target for myocardial diseases," *Circulation Research*, vol. 116, no. 1, pp. 138–149, 2015.
- [121] A. P. Saraswati, S. M. Ali Hussaini, N. H. Krishna, B. N. Babu, and A. Kamal, "Glycogen synthase kinase-3 and its inhibitors: potential target for various therapeutic conditions," *European Journal of Medicinal Chemistry*, vol. 144, pp. 843–858, 2018.
- [122] S. Lovestone, M. Boada, B. Dubois et al., "A phase II trial of tideglusib in Alzheimer's disease," *Journal of Alzheimer's Disease*, vol. 45, no. 1, pp. 75–88, 2015.
- [123] T. Bourhill, A. Narendran, and R. N. Johnston, "Enzastaurin: a lesson in drug development," *Critical Reviews in Oncology/Hematology*, vol. 112, pp. 72–79, 2017.
- [124] G. Lombardi, A. Pambuku, L. Bellu et al., "Effectiveness of antiangiogenic drugs in glioblastoma patients: a systematic review and meta-analysis of randomized clinical trials," *Critical Reviews in Oncology/Hematology*, vol. 111, pp. 94–102, 2017.
- [125] A. I. Rojo, O. N. Medina-Campos, P. Rada et al., "Signaling pathways activated by the phytochemical nordihydroguaiaretic acid contribute to a Keap1-independent regulation of Nrf2 stability: role of glycogen synthase kinase-3," *Free Radical Biology & Medicine*, vol. 52, no. 2, pp. 473–487, 2012.
- [126] V. Palomo and A. Martinez, "Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014–2015)," *Expert Opinion on Therapeutic Patents*, vol. 27, no. 6, pp. 657–666, 2017.
- [127] P. Rada, A. I. Rojo, N. Evrard-Todeschi et al., "Structural and functional characterization of Nrf2 degradation by the glycogen synthase kinase 3/ β -TrCP axis," *Molecular and Cellular Biology*, vol. 32, no. 17, pp. 3486–3499, 2012.
- [128] B. E. Hast, D. Goldfarb, K. M. Mulvaney et al., "Proteomic analysis of ubiquitin ligase KEAP1 reveals associated proteins that inhibit NRF2 ubiquitination," *Cancer Research*, vol. 73, no. 7, pp. 2199–2210, 2013.
- [129] A. Jain, T. Lamark, E. Sjøttem et al., "p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response element-driven gene transcription," *Journal of Biological Chemistry*, vol. 285, no. 29, pp. 22576–22591, 2010.
- [130] A. Lau, X. J. Wang, F. Zhao et al., "A noncanonical mechanism of Nrf2 activation by autophagy deficiency: direct interaction between Keap1 and p62," *Molecular and Cellular Biology*, vol. 30, no. 13, pp. 3275–3285, 2010.
- [131] M. Komatsu, H. Kurokawa, S. Waguri et al., "The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1," *Nature Cell Biology*, vol. 12, no. 3, pp. 213–223, 2010.
- [132] S. Sarkar and D. C. Rubinsztein, "Small molecule enhancers of autophagy for neurodegenerative diseases," *Molecular Biosystems*, vol. 4, no. 9, pp. 895–901, 2008.
- [133] Y. Mizunoe, M. Kobayashi, Y. Sudo et al., "Trehalose protects against oxidative stress by regulating the Keap1-Nrf2 and autophagy pathways," *Redox Biology*, vol. 15, pp. 115–124, 2018.
- [134] S. Dhakshinamoorthy, A. K. Jain, D. A. Bloom, and A. K. Jaiswal, "Bach1 competes with Nrf2 leading to negative regulation of the antioxidant response element (ARE)-mediated NAD(P)H:quinone oxidoreductase 1 gene expression and induction in response to antioxidants," *Journal of Biological Chemistry*, vol. 280, no. 17, pp. 16891–16900, 2005.
- [135] O. C. Attucks, K. J. Jasmer, M. Hannink et al., "Induction of heme oxygenase 1 (HMOX1) by HPP-4382: a novel modulator of Bach1 activity," *PLoS One*, vol. 9, no. 7, article e101044, 2014.
- [136] M. Ramos-Gomez, P. M. Dolan, K. Itoh, M. Yamamoto, and T. W. Kensler, "Interactive effects of nrf2 genotype and oltipraz on benzo[a]pyrene-DNA adducts and tumor yield in mice," *Carcinogenesis*, vol. 24, no. 3, pp. 461–467, 2003.
- [137] C. Xu, M. T. Huang, G. Shen et al., "Inhibition of 7,12-dimethylbenz(a)anthracene-induced skin tumorigenesis in C57BL/6 mice by sulforaphane is mediated by nuclear factor E2-related factor 2," *Cancer Research*, vol. 66, no. 16, pp. 8293–8296, 2006.
- [138] L. M. Solis, C. Behrens, W. Dong et al., "Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features," *Clinical Cancer Research*, vol. 16, no. 14, pp. 3743–3753, 2010.
- [139] T. Shibata, T. Ohta, K. I. Tong et al., "Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy," *Proceedings of the National*

- Academy of Sciences of the United States of America*, vol. 105, no. 36, pp. 13568–13573, 2008.
- [140] T. Ohta, K. Iijima, M. Miyamoto et al., “Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth,” *Cancer Research*, vol. 68, no. 5, pp. 1303–1309, 2008.
- [141] L. Milkovic, N. Zarkovic, and L. Saso, “Controversy about pharmacological modulation of Nrf2 for cancer therapy,” *Redox Biology*, vol. 12, pp. 727–732, 2017.
- [142] H. Kitamura and H. Motohashi, “NRF2 addiction in cancer cells,” *Cancer Science*, vol. 109, no. 4, pp. 900–911, 2018.
- [143] S. H. Ki, I. J. Cho, D. W. Choi, and S. G. Kim, “Glucocorticoid receptor (GR)-associated SMRT binding to C/EBP β TAD and Nrf2 Neh4/5: role of SMRT recruited to GR in GSTA2 gene repression,” *Molecular and Cellular Biology*, vol. 25, no. 10, pp. 4150–4165, 2005.
- [144] E. J. Choi, B. J. Jung, S. H. Lee et al., “A clinical drug library screen identifies clobetasol propionate as an NRF2 inhibitor with potential therapeutic efficacy in KEAP1 mutant lung cancer,” *Oncogene*, vol. 36, no. 37, pp. 5285–5295, 2017.
- [145] X. J. Wang, J. D. Hayes, C. J. Henderson, and C. R. Wolf, “Identification of retinoic acid as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor α ,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 104, no. 49, pp. 19589–19594, 2007.
- [146] H. Wang, K. Liu, M. Geng et al., “RXR α inhibits the NRF2-ARE signaling pathway through a direct interaction with the Neh7 domain of NRF2,” *Cancer Research*, vol. 73, no. 10, pp. 3097–3108, 2013.
- [147] D. Ren, N. F. Villeneuve, T. Jiang et al., “Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 108, no. 4, pp. 1433–1438, 2011.
- [148] B. Harder, W. Tian, J. J. la Clair et al., “Brusatol overcomes chemoresistance through inhibition of protein translation,” *Molecular Carcinogenesis*, vol. 56, no. 5, pp. 1493–1500, 2017.
- [149] S. Vartanian, T. P. Ma, J. Lee et al., “Application of mass spectrometry profiling to establish brusatol as an inhibitor of global protein synthesis,” *Molecular & Cellular Proteomics*, vol. 15, no. 4, pp. 1220–1231, 2016.
- [150] J. Zhu, H. Wang, F. Chen et al., “An overview of chemical inhibitors of the Nrf2-ARE signaling pathway and their potential applications in cancer therapy,” *Free Radical Biology & Medicine*, vol. 99, pp. 544–556, 2016.
- [151] X. Tang, H. Wang, L. Fan et al., “Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs,” *Free Radical Biology & Medicine*, vol. 50, no. 11, pp. 1599–1609, 2011.
- [152] Y. Zhong, F. Zhang, Z. Sun et al., “Drug resistance associates with activation of Nrf2 in MCF-7/DOX cells, and wogonin reverses it by down-regulating Nrf2-mediated cellular defense response,” *Molecular Carcinogenesis*, vol. 52, no. 10, pp. 824–834, 2013.
- [153] A. K. Pandurangan, S. K. Ananda Sadagopan, P. Dharmalingam, and S. Ganapasam, “Luteolin, a bioflavonoid inhibits Azoxymethane-induced colorectal cancer through activation of Nrf2 signaling,” *Toxicology Mechanisms and Methods*, vol. 24, no. 1, pp. 13–20, 2014.
- [154] A. Limonciel and P. Jennings, “A review of the evidence that ochratoxin A is an Nrf2 inhibitor: implications for nephrotoxicity and renal carcinogenicity,” *Toxins*, vol. 6, no. 1, pp. 371–379, 2014.
- [155] A. Arlt, S. Sebens, S. Krebs et al., “Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity,” *Oncogene*, vol. 32, no. 40, pp. 4825–4835, 2013.
- [156] A. Manna, S. de Sarkar, S. de, A. K. Bauri, S. Chattopadhyay, and M. Chatterjee, “The variable chemotherapeutic response of Malabaricone-A in leukemic and solid tumor cell lines depends on the degree of redox imbalance,” *Phytomedicine*, vol. 22, no. 7-8, pp. 713–723, 2015.
- [157] T. Tarumoto, T. Nagai, K. Ohmine et al., “Ascorbic acid restores sensitivity to imatinib via suppression of Nrf2-dependent gene expression in the imatinib-resistant cell line,” *Experimental Hematology*, vol. 32, no. 4, pp. 375–381, 2004.
- [158] A. Singh, S. Venkannagari, K. H. Oh et al., “Small molecule inhibitor of NRF2 selectively intervenes therapeutic resistance in KEAP1-deficient NSCLC tumors,” *ACS Chemical Biology*, vol. 11, no. 11, pp. 3214–3225, 2016.
- [159] K. Tsuchida, T. Tsujita, M. Hayashi et al., “Halofuginone enhances the chemo-sensitivity of cancer cells by suppressing NRF2 accumulation,” *Free Radical Biology & Medicine*, vol. 103, pp. 236–247, 2017.
- [160] M. J. Bollong, H. Yun, L. Sherwood, A. K. Woods, L. L. Lairson, and P. G. Schultz, “A small molecule inhibits deregulated NRF2 transcriptional activity in cancer,” *ACS Chemical Biology*, vol. 10, no. 10, pp. 2193–2198, 2015.
- [161] J. Zhang, L. Su, Q. Ye et al., “Discovery of a novel Nrf2 inhibitor that induces apoptosis of human acute myeloid leukemia cells,” *Oncotarget*, vol. 8, no. 5, pp. 7625–7636, 2017.
- [162] R. Steel, J. Cowan, E. Payerne, M. A. O’Connell, and M. Searcey, “Anti-inflammatory effect of a cell-penetrating peptide targeting the Nrf2/Keap1 interaction,” *ACS Medicinal Chemistry Letters*, vol. 3, no. 5, pp. 407–410, 2012.
- [163] Z. Y. Jiang, L.-L. Xu, M. C. Lu et al., “Structure-activity and structure-property relationship and exploratory in vivo evaluation of the nanomolar Keap1-Nrf2 protein-protein interaction inhibitor,” *Journal of Medicinal Chemistry*, vol. 58, no. 16, pp. 6410–6421, 2015.
- [164] J. G. Yonchuk, J. P. Foley, B. J. Bolognese et al., “Characterization of the potent, selective Nrf2 activator, 3-(pyridin-3-ylsulfonyl)-5-(trifluoromethyl)-2H-chromen-2-one, in cellular and in vivo models of pulmonary oxidative stress,” *The Journal of Pharmacology and Experimental Therapeutics*, vol. 363, no. 1, pp. 114–125, 2017.
- [165] H.-P. Sun, Z.-Y. Jiang, M.-Y. Zhang et al., “Novel protein-protein interaction inhibitor of Nrf2–Keap1 discovered by structure-based virtual screening,” *MedChemComm*, vol. 5, no. 1, pp. 93–98, 2014.
- [166] T. G. Davies, W. E. Wixted, J. E. Coyle et al., “Monoacidic inhibitors of the Kelch-like ECH-associated protein 1: nuclear factor erythroid 2-related factor 2 (KEAP1:NRF2) protein-protein interaction with high cell potency identified by fragment-based discovery,” *Journal of Medicinal Chemistry*, vol. 59, no. 8, pp. 3991–4006, 2016.

- [167] K. Itoh, N. Wakabayashi, Y. Katoh et al., “Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain,” *Genes & Development*, vol. 13, no. 1, pp. 76–86, 1999.
- [168] K. Taguchi, H. Motohashi, and M. Yamamoto, “Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution,” *Genes to Cells*, vol. 16, no. 2, pp. 123–140, 2011.